TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31171419

Group type: EXPERIMENTAL
Intervention: D- VTd group (n=543)
Number of subjects: 1085

Group type: COMPARATOR
Intervention: VTd group (n=542)
Number of subjects: 1085
Study: 28050917

Group type: EXPERIMENTAL
Intervention: Caffeine (4 mg.kg‐1, capsule)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 26171624

Group type: EXPERIMENTAL
Intervention: Triclosan-coated sutures (group 1)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Sutures without triclosan (group 2)
Number of subjects: 101
Study: 23235141

Group type: EXPERIMENTAL
Intervention: Social Skills Training (SST)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 31
Study: 21622669

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent
Number of subjects: 161

Group type: COMPARATOR
Intervention: Bare-metal stent
Number of subjects: 161
Study: 18283068

Group type: EXPERIMENTAL
Intervention: Graded cystine test diets with generous amounts of methionine
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Cyst(e)ine intake <18 mg/kg per day
Number of subjects: 47
Study: 17082779

Group type: EXPERIMENTAL
Intervention: Lisofylline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard remission-induction therapy (idarubicin plus cytarabine)
Number of subjects: 0
Study: 12971706

Group type: EXPERIMENTAL
Intervention: Cold pack during passive knee joint stretching
Number of subjects: 71

Group type: COMPARATOR
Intervention: Hot pack during passive knee joint stretching
Number of subjects: 71
Study: 11195305

Group type: EXPERIMENTAL
Intervention: Go/no-go signal precue
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Secondary working memory task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Completely non-informative precues (congruent, incongruent, unrelated)
Number of subjects: 0
Study: 9181158

Group type: EXPERIMENTAL
Intervention: Intravenous phentolamine (0.5 mg/kg over 30 min)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Opioid epidural test blockade (control)
Number of subjects: 37
Study: 8344801

Group type: EXPERIMENTAL
Intervention: Myopia treatment
Number of subjects: 238
Study: 2870010

Group type: EXPERIMENTAL
Intervention: Terbutaline (0.25 mg injected subcutaneously)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Metaproterenol (inhaled via metered dose inhaler)
Number of subjects: 16
Study: 31389323

Group type: EXPERIMENTAL
Intervention: Checklist group (CG)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Non-checklist group (NCG)
Number of subjects: 28
Study: 29421967

Group type: EXPERIMENTAL
Intervention: Psychological Inoculation (PI)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Health Education (HE)
Number of subjects: 60
Study: 27379563

Group type: EXPERIMENTAL
Intervention: Active rTMS (n = 13)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sham (n = 11)
Number of subjects: 24
Study: 24886287

Group type: EXPERIMENTAL
Intervention: Retrospective continuous glucose monitoring (r-CGM)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Self-monitoring of blood glucose (SMBG)
Number of subjects: 102
Study: 22848898

Group type: EXPERIMENTAL
Intervention: Immediate loading regimen
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Early loading regimen (6 weeks)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Conventional/delayed loading regimen (12 weeks)
Number of subjects: 40

Group type: COMPARATOR
Intervention: All loading groups
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Bone types 1 and 2 (grouped together)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Bone type 3
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Bone type 4
Number of subjects: 40
Study: 21084039

Group type: EXPERIMENTAL
Intervention: Subcutaneous ustekinumab
Number of subjects: 130

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 130
Study: 18996246

Group type: EXPERIMENTAL
Intervention: Home-based passive leg cycle exercise training (36 sessions)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Home-based passive leg cycle exercise training
Number of subjects: 17
Study: 16417078

Group type: EXPERIMENTAL
Intervention: PvuII polymorphism of the ER-alpha gene
Number of subjects: 93
Study: 12641682

Group type: COMPARATOR
Intervention: EMLA + air/O2
Number of subjects: 120

Group type: COMPARATOR
Intervention: 50% N2O/50% O2
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: EMLA + 50% N2O/50% O2
Number of subjects: 120
Study: 10489821

Group type: EXPERIMENTAL
Intervention: Repeated episodes of fever and antibiotic treatment in early life
Number of subjects: 15043

Group type: EXPERIMENTAL
Intervention: Number of fever episodes and antibiotic courses in asthmatic children
Number of subjects: 15043

Group type: EXPERIMENTAL
Intervention: Recurrent early childhood infections in asthmatic children
Number of subjects: 15043

Group type: EXPERIMENTAL
Intervention: Repeated early childhood infections in nonatopic asthmatic children
Number of subjects: 15043
Study: 8702450

Group type: COMPARATOR
Intervention: 5-aminosalicylic acid (ASA)
Number of subjects: 90

Group type: COMPARATOR
Intervention: sulfapyridine (SP)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: sulfasalazine (SSZ)
Number of subjects: 90
Study: 1881997

Group type: EXPERIMENTAL
Intervention: 400 mg carbamazepine
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 6693665

Group type: EXPERIMENTAL
Intervention: Bitolterol mesylate aerosol
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Combination of bitolterol and theophylline
Number of subjects: 73

Group type: COMPARATOR
Intervention: Theophylline alone
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 73
Study: 30497641

Group type: EXPERIMENTAL
Intervention: Exercise training group (752 patients)
Number of subjects: 1494

Group type: COMPARATOR
Intervention: Usual care group (742 patients)
Number of subjects: 1494

Group type: EXPERIMENTAL
Intervention: Middle PA tertile
Number of subjects: 1494

Group type: EXPERIMENTAL
Intervention: Upper PA tertile
Number of subjects: 1494
Study: 27510538

Group type: EXPERIMENTAL
Intervention: Low-caloric diet (LCD) (800-1000 kcal/d)
Number of subjects: 383

Group type: EXPERIMENTAL
Intervention: Lipid signature
Number of subjects: 383

Group type: COMPARATOR
Intervention: Clinical data-only model
Number of subjects: 383
Study: 24708505

Group type: EXPERIMENTAL
Intervention: /i:/ (ZMM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: /o:/ (OOM)
Number of subjects: 0
Study: 23122453

Group type: EXPERIMENTAL
Intervention: Endoscopic variceal ligation (EVL) followed by one session of argon plasma coagulation (APC)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Endoscopic variceal ligation (EVL) alone
Number of subjects: 60
Study: 20232036

Group type: EXPERIMENTAL
Intervention: GRV = 500 ml
Number of subjects: 329

Group type: COMPARATOR
Intervention: GRV = 200 ml
Number of subjects: 329
Study: 16969601

Group type: EXPERIMENTAL
Intervention: Unprepped CT colonography with low fiber diet and stool tagging
Number of subjects: 28

Group type: COMPARATOR
Intervention: Prepped CT colonography with low fiber diet, tagging, and magnesium citrate cleansing preparation
Number of subjects: 28
Study: 17535287

Group type: EXPERIMENTAL
Intervention: Essential oil-containing mouthrinse (Cool Mint Listerine Antiseptic)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Negative control
Number of subjects: 15
Study: 15026800

Group type: EXPERIMENTAL
Intervention: Oral capecitabine (1250 mg m(‐2) twice daily, days 1‐14 every 21 days; n=603)
Number of subjects: 1207

Group type: COMPARATOR
Intervention: Intravenous 5-fluorouracil/leucovorin (5‐FU/LV; Mayo Clinic regimen; n=604)
Number of subjects: 1207

Group type: EXPERIMENTAL
Intervention: Oral capecitabine
Number of subjects: 1207

Group type: COMPARATOR
Intervention: Intravenous 5-fluorouracil/leucovorin (5‐FU/LV)
Number of subjects: 1207
Study: 11432159

Group type: EXPERIMENTAL
Intervention: 3-D video glasses
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control (no video)
Number of subjects: 39
Study: 9083591

Group type: EXPERIMENTAL
Intervention: Village-based intervention for behavior change and community health promotion
Number of subjects: 600
Study: 8473492

Group type: EXPERIMENTAL
Intervention: guanadrel
Number of subjects: 10
Study: 3513634

Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 31548125

Group type: EXPERIMENTAL
Intervention: Primary School Students (PS)
Number of subjects: 79220

Group type: EXPERIMENTAL
Intervention: Middle School Students (MS)
Number of subjects: 79220
Study: 30782304

Group type: EXPERIMENTAL
Intervention: Intensive sport rehabilitation for the first year
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control group (no sport rehabilitation)
Number of subjects: 160
Study: 28804169

Group type: EXPERIMENTAL
Intervention: Infants weighing 2.00–2.49 kg
Number of subjects: 22906

Group type: EXPERIMENTAL
Intervention: Infants weighing 1.50–1.99 kg
Number of subjects: 22906

Group type: EXPERIMENTAL
Intervention: Infants weighing < 1.50 kg
Number of subjects: 22906
Study: 25495503

Group type: EXPERIMENTAL
Intervention: Comprehensive dietary advice based on the British Society of Rheumatology Guidelines
Number of subjects: 30

Group type: COMPARATOR
Intervention: Basic advice regarding compliance with therapy and weight loss
Number of subjects: 30
Study: 23478168

Group type: EXPERIMENTAL
Intervention: Home-based Wii Balance Board System (WBBS) training for 12 weeks
Number of subjects: 36
Study: 21586987

Group type: EXPERIMENTAL
Intervention: Interactive multimedia CD educational intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 19504118

Group type: EXPERIMENTAL
Intervention: High-Intensity Resistance Training (HI)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Low-Intensity Resistance Training (LO)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 32
Study: 16842456

Group type: EXPERIMENTAL
Intervention: NSAID prescription with diagnostic codes for UGIE and endoscopic procedural codes
Number of subjects: 906

Group type: EXPERIMENTAL
Intervention: Algorithm validation in patients with overlapping NSAID prescription
Number of subjects: 906

Group type: EXPERIMENTAL
Intervention: Algorithm including in-patient ICD-9 code for gastric or duodenal ulcer and gastrointestinal bleeding combined with upper endoscopy
Number of subjects: 906

Group type: COMPARATOR
Intervention: Control group of patients prescribed NSAIDs without UGIE
Number of subjects: 906

Group type: EXPERIMENTAL
Intervention: Diagnostic codes for UGIE
Number of subjects: 906
Study: 12957759

Group type: EXPERIMENTAL
Intervention: Crystalloid cardioplegic solution (Group A, n=9)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Warm blood cardioplegic solution (Group B, n=8)
Number of subjects: 17
Study: 11199243

Group type: EXPERIMENTAL
Intervention: Computer intervention with an interactive soap-opera format
Number of subjects: 178

Group type: COMPARATOR
Intervention: Comparison group
Number of subjects: 178
Study: 9172668

Group type: EXPERIMENTAL
Intervention: Dynamic screening sequence evaluation of signal intensity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MRI contrast enhancement
Number of subjects: 0
Study: 8258611

Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (4 mg, administered four times at 4-hour intervals)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 3929584

Group type: COMPARATOR
Intervention: Atenolol (100 mg once daily) plus labetalol placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Labetalol (200 mg twice daily) plus atenolol placebo
Number of subjects: 10

Group type: COMPARATOR
Intervention: Active atenolol without labetalol placebo
Number of subjects: 10
Study: 31374475

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 29210513

Group type: EXPERIMENTAL
Intervention: CD gel with 1 mg/2 mL budesonide
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: CD gel (without budesonide)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Topical steroid cream
Number of subjects: 36
Study: 26246049

Group type: EXPERIMENTAL
Intervention: Brief intervention to create smoke-free homes
Number of subjects: 286
Study: 25217098

Group type: EXPERIMENTAL
Intervention: ASPIRE-Group
Number of subjects: 481

Group type: EXPERIMENTAL
Intervention: ASPIRE-Phone
Number of subjects: 481

Group type: COMPARATOR
Intervention: MOVE!
Number of subjects: 481
Study: 23045541

Group type: EXPERIMENTAL
Intervention: Patient Navigation (PN) program
Number of subjects: 1267

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1267
Study: 20185012

Group type: EXPERIMENTAL
Intervention: Ezetimibe added to atorvastatin 10 mg for 12 weeks
Number of subjects: 1053

Group type: EXPERIMENTAL
Intervention: Ezetimibe added to atorvastatin 10 mg
Number of subjects: 1053

Group type: COMPARATOR
Intervention: Atorvastatin 20 mg or atorvastatin 40 mg
Number of subjects: 1053
Study: 17319927

Group type: EXPERIMENTAL
Intervention: Omeprazole at half the starting dose, once daily before breakfast
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Ranitidine 10 mg/kg/day, divided in two doses
Number of subjects: 48

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Post-maintenance follow-up
Number of subjects: 48
Study: 15151791

Group type: EXPERIMENTAL
Intervention: Intervention group (IG) received a telephone call at 2 weeks, 2 months and 4 months in addition to normal treatment
Number of subjects: 126

Group type: COMPARATOR
Intervention: Control group (CG) received normal treatment
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Overall compliance
Number of subjects: 126

Group type: COMPARATOR
Intervention: Control group (CG) mean compliance
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Intervention group (IG) mean compliance
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Intervention group (IG) patients controlled
Number of subjects: 126

Group type: COMPARATOR
Intervention: Control group (CG) patients controlled
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Reduction of absolute risk (RAR)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Reduction of relative risk (RRR)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Number needed to treat (NI)
Number of subjects: 126
Study: 11352203

Group type: EXPERIMENTAL
Intervention: Revealed words (completed word fragments)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intact words (presented intact)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Revealed words (same word as judged)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Revealed words (different word from judged)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: More distorted test items
Number of subjects: 0
Study: 9752991

Group type: EXPERIMENTAL
Intervention: High WBF (13.5 g/day)
Number of subjects: 1429

Group type: COMPARATOR
Intervention: Low WBF (2 g/day)
Number of subjects: 1429
Study: 8185367

Group type: EXPERIMENTAL
Intervention: Modular feed
Number of subjects: 35

Group type: COMPARATOR
Intervention: Sterile ready to use paediatric feed
Number of subjects: 35
Study: 3589921

Group type: EXPERIMENTAL
Intervention: Mezlocillin (4 grams every six hours)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Clindamycin (600 milligrams every six hours) and Gentamicin (loading dose of 2.0 milligrams per kilogram, then 1.5 milligrams per kilogram every eight hours)
Number of subjects: 130
Study: 30704890

Group type: EXPERIMENTAL
Intervention: Oral vitamin B complex (B1, B6, and B12) once daily for 12 weeks
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 29786677

Group type: EXPERIMENTAL
Intervention: Combined rehabilitative physiotherapeutic treatment including modulated sinusoidal currents, total wrapping with Rapan saline solution, and sedative inhalations of peony root extract.
Number of subjects: 59

Group type: COMPARATOR
Intervention: Conventional medical treatment (control group).
Number of subjects: 59
Study: 26699431

Group type: EXPERIMENTAL
Intervention: Exercise (2 × 60‐min cycle exercise/day at 50% of hypoxia‐specific peak power output)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control (no exercise)
Number of subjects: 14
Study: 24117681

Group type: EXPERIMENTAL
Intervention: 0.8 g/kg alcohol
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study: 22763789

Group type: EXPERIMENTAL
Intervention: DLE-SLE+
Number of subjects: 43

Group type: COMPARATOR
Intervention: DLE+SLE+
Number of subjects: 43

Group type: COMPARATOR
Intervention: Healthy and DLE+SLE-
Number of subjects: 43
Study: 20816858

Group type: EXPERIMENTAL
Intervention: Norfloxacin 400 mg twice daily for 4 weeks
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 17852859

Group type: EXPERIMENTAL
Intervention: BIO-THREE (9 tablets per day for 4 weeks)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: BIO-THREE
Number of subjects: 20
Study: 16255713

Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-clinical data
Number of subjects: 0
Study: 11893230

Group type: EXPERIMENTAL
Intervention: Drotrecogin alfa (activated) 24 microg/kg/h for 96 hours
Number of subjects: 1690

Group type: EXPERIMENTAL
Intervention: Drotrecogin alfa (activated)
Number of subjects: 1690
Study: 10386279

Group type: EXPERIMENTAL
Intervention: Isoflurane anesthesia (1.2% to 2.0% in 50% oxygen) with intravenous thiopental sodium (3 to 5 mg/kg) and succinylcholine (0.5 to 1.0 mg/kg) for tracheal intubation.
Number of subjects: 36
Study: 8610952

Group type: EXPERIMENTAL
Intervention: Dietary calcium supplementation
Number of subjects: 1231
Study: 1986602

Group type: EXPERIMENTAL
Intervention: Fluoxetine administration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (basal)
Number of subjects: 0
Study: 6863643

Group type: EXPERIMENTAL
Intervention: 1% crude coal tar with suberythemogenic UVB
Number of subjects: 0

Group type: COMPARATOR
Intervention: Petrolatum with erythemogenic UVB
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5% tar extract in oil with suberythemogenic UVB
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tar extract in oil versus crude coal tar in petrolatum with suberythemogenic UVB
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tar extract in oil without UV radiation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Erythemogenic UVB with or without coal tars
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Suberythemogenic UVB with adjunctive coal tar
Number of subjects: 0
Study: 31077576

Group type: EXPERIMENTAL
Intervention: Novel phosphodiesterase-4 inhibitor (CHF6001)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Simulation study with simple linear mixed-effects model
Number of subjects: 0
Study: 28296732

Group type: EXPERIMENTAL
Intervention: 0.05 mg/kg oxycodone
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg oxycodone
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: 0.15 mg/kg oxycodone
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg oxycodone
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: 0.159 mg/kg oxycodone (ED95)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: 0.020 mg/kg oxycodone (ED50)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Control group (0 mg/kg oxycodone)
Number of subjects: 95
Study: 26567274

Group type: EXPERIMENTAL
Intervention: 300 mg Bupropion Sustained Release
Number of subjects: 312

Group type: COMPARATOR
Intervention: 150 mg Bupropion Sustained Release
Number of subjects: 312

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 312
Study: 24950690

Group type: EXPERIMENTAL
Intervention: Second-generation telecare intervention (package of equipment and monitoring services for 12 months)
Number of subjects: 2600

Group type: COMPARATOR
Intervention: Usual health and social care (control group)
Number of subjects: 2600
Study: 23103313

Group type: EXPERIMENTAL
Intervention: Anterior temporal lobectomy (ATL)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Seizure free status, one or no antiepileptic drug (AED), EEG without epileptiform abnormalities
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Discontinuation of enzyme‐inducing AEDs
Number of subjects: 50

Group type: COMPARATOR
Intervention: Age-matched healthy married males (control group)
Number of subjects: 50
Study: 19442523

Group type: EXPERIMENTAL
Intervention: BoNT‐A injections
Number of subjects: 20
Study: 17878762

Group type: EXPERIMENTAL
Intervention: Low-dose hydrocortisone
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: High-dose hydrocortisone
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Bradykinin infusion
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Bradykinin, acetylcholine, sodium nitroprusside infusions
Number of subjects: 12
Study: 15732860

Group type: EXPERIMENTAL
Intervention: Scaling and root planing followed by local application of doxycycline (SRP-D)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Scaling and root planing (SRP)
Number of subjects: 16
Study: 10645924

Group type: EXPERIMENTAL
Intervention: Catheter ablation
Number of subjects: 10000

Group type: COMPARATOR
Intervention: Amiodarone
Number of subjects: 10000
Study: 9337579

Group type: EXPERIMENTAL
Intervention: Encoding tasks during study for high- and low-frequency words
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Repetition to increase recognition performance
Number of subjects: 5

Group type: COMPARATOR
Intervention: Attention/likelihood theory
Number of subjects: 5
Study: 8448093

Group type: EXPERIMENTAL
Intervention: Sciatic nerve block technique 1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sciatic nerve block technique 2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sciatic nerve block (both techniques)
Number of subjects: 0
Study: 3542618

Group type: COMPARATOR
Intervention: Conventional treatment with one or two daily doses of insulin (Group A)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Intensified treatment with nine daily injections of fast‐acting insulin for ten days and for 7 days after 15 months (Group B)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Intensified treatment with nine daily injections of fast‐acting insulin (Group B)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Second period with strict control (Group B)
Number of subjects: 15